comment
shafagati
n
et
al
enhanc
detect
respiratori
pathogen
nanotrap
particl
virul
http
dx
season
respiratori
viru
infect
repres
signific
burden
global
public
health
especi
highrisk
group
children
immunocompromis
popul
given
year
influenza
viru
alon
infect
world
popul
result
million
case
sever
ill
death
respiratori
syncyti
viru
rsv
lead
caus
acut
respiratori
infect
children
claim
infant
young
children
addit
yearli
morbid
mortal
associ
number
virus
includ
parainfluenza
viru
human
metapneumoviur
rhinoviru
adenoviru
coronaviru
cov
apart
season
outbreak
virus
tend
evolutionarili
dynam
natur
result
frequent
emerg
reemerg
novel
strain
within
past
decad
world
seen
pandem
novel
influenza
numer
human
infect
avian
influenza
subtyp
emerg
spread
novel
coronavirus
sever
acut
respiratori
syndrom
sar
cov
middl
east
respiratori
syndrom
mer
cov
therefor
accur
effici
identif
respiratori
virus
critic
manag
infect
context
season
outbreak
pandem
event
virus
common
infecti
agent
respiratori
tract
respiratori
viru
infect
reliabl
diagnos
clinic
characterist
alon
sinc
symptom
specif
viral
bacteri
etiolog
laboratori
identif
isol
vital
compon
respiratori
infect
treatment
prevent
control
sinc
discoveri
influenza
viru
tradit
method
diagnosi
reli
isol
propag
viru
appropri
cultur
system
howev
techniqu
limit
clinic
use
due
number
factor
includ
assay
time
expertis
requir
accur
interpret
lack
adequ
system
virus
advent
molecular
detect
viral
nucleic
acid
respiratori
virus
revolution
laboratori
diagnosi
surveil
viral
pathogen
type
test
begun
supplant
tradit
laboratori
methodolog
nevertheless
nucleic
acid
amplif
test
increas
sensit
decreas
diagnost
time
immens
problem
still
exist
fals
neg
low
valu
work
improv
test
warrant
work
shafagati
et
al
present
issu
repres
advanc
clinic
diagnosi
respiratori
pathogen
previou
studi
group
demonstr
nanotrap
particl
effect
rapidli
captur
number
pathogen
articl
shafagati
et
al
util
technolog
concentr
viru
clinic
relev
human
specimen
incub
nanotrap
particl
prior
nucleic
acid
extract
enhanc
detect
sever
subtyp
season
influenza
viru
avian
influenza
viru
well
cov
rsv
nasal
aspir
nasal
swab
saliva
influenza
alon
detect
capac
increas
addit
sinc
respiratori
viru
coinfect
occur
acut
respiratori
tract
infect
children
author
show
particl
enhanc
detect
multipl
respiratori
virus
singl
sampl
result
present
boon
increas
sensit
laboratori
diagnosi
also
clinic
epidemiolog
aspect
respiratori
viru
pathogenesi
transmiss
enhanc
detect
could
prolong
abil
identifi
viru
follow
infect
onset
symptom
give
better
clinic
epidemiolog
pictur
viral
shed
furthermor
techniqu
could
appli
asymptomat
contact
individu
high
risk
viral
exposur
due
proxim
infect
individu
potenti
sourc
zoonot
transmiss
new
techniqu
concentr
enhanc
detect
respiratori
virus
one
present
shafagati
et
al
provid
advantag
rapid
diagnosi
human
infect
also
increas
sensit
earli
detect
surveil
system
infecti
diseas
surveil
system
critic
enact
prompt
control
prevent
measur
prevent
widespread
outbreak
start
world
health
organ
global
influenza
surveil
network
involv
collabor
laboratori
countri
constantli
monitor
isol
influenza
virus
human
anim
data
crucial
coordin
unifi
respons
season
pandem
control
influenza
one
limit
influenza
surveil
abil
detect
viru
environment
anim
sampl
may
low
viral
abund
therefor
concentr
nanotrap
particl
may
increas
detect
influenza
sampl
moreov
articl
author
show
nanotrap
particl
increas
molecular
detect
also
use
increas
viral
isol
enhanc
isol
influenza
virus
anim
human
would
invalu
understand
influenza
epidemiolog
pathogenesi
also
provid
increas
resourc
rapid
vaccin
develop
similar
advantag
could
also
appli
similar
surveil
system
search
cov
human
camel
bat
overal
result
studi
shafagati
et
al
present
issu
virul
repres
interest
step
forward
molecular
detect
isol
respiratori
virus
howev
sever
limit
still
exist
work
warrant
understand
exact
mechan
mechan
nanotrap
particl
bind
viru
differ
particl
could
har
multiplex
individu
sampl
addit
addit
studi
done
util
particl
mani
virus
individu
viabl
viral
subtyp
well
relev
matric
ie
avian
human
stool
mammalian
nasal
aspir
determin
full
capabl
individu
particl
type
final
result
valid
multipl
team
determin
extent
use
nanotrap
particl
clinic
laboratori
field
set
potenti
conflict
interest
disclos
